-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
HIMS:NYE- (USD)
COMMON STOCK | Household & Personal Products |
Last Closing
USD 21.56Change
-1.60 (-6.91)%Market Cap
USD 5.48BVolume
0.01BVerdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Household & Personal Products |
Last Closing
USD 21.56Change
-1.60 (-6.91)%Market Cap
USD 5.48BVolume
0.01BVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
PG | Procter & Gamble Company |
-1.70 (-1.02%) |
USD 397.83B |
UL | Unilever PLC ADR |
-0.36 (-0.65%) |
USD 140.17B |
CL | Colgate-Palmolive Company |
-1.13 (-1.15%) |
USD 79.80B |
KMB | Kimberly-Clark Corporation |
-1.15 (-0.83%) |
USD 46.86B |
EL | Estee Lauder Companies Inc |
-4.46 (-4.02%) |
USD 40.82B |
CHD | Church & Dwight Company Inc |
-0.33 (-0.32%) |
USD 25.55B |
KAOCF | Kao Corporation |
N/A |
USD 19.69B |
UNCHF | Unicharm Corporation |
-0.58 (-1.79%) |
USD 18.82B |
CLX | The Clorox Company |
-0.13 (-0.10%) |
USD 16.90B |
SSDOF | Shiseido Company Limited |
N/A |
USD 12.48B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
EDOC:LSE | Global X Telemedicine & D.. | 4.72 % | 0.00 % |
-0.01 (-0.11%) |
USD 4.59M |
EDOG:LSE | Global X Telemedicine & D.. | 4.72 % | 0.00 % |
-0.01 (-0.11%) |
USD 0.14M |
DDOC:F | Global X Telemedicine & D.. | 4.10 % | 0.00 % |
+0.01 (+-0.11%) |
USD 4.76M |
EDOC:SW | Global X Telemedicine & D.. | 4.10 % | 0.00 % |
-0.02 (-0.11%) |
USD 4.55M |
FDHT | 3.36 % | 0.00 % |
N/A |
N/A | |
FDHT:XETRA | Fidelity Digital Health U.. | 3.00 % | 0.00 % |
-0.01 (-0.11%) |
USD 2.81M |
WELP:LSE | HAN-GINS Indxx Healthcare.. | 2.86 % | 0.00 % |
-1.25 (-0.11%) |
USD 0.02B |
FDOC:LSE | Fidelity Digital Health U.. | 2.75 % | 0.00 % |
N/A |
USD 2.81M |
WELL:PA | HAN-GINS Indxx Healthcare.. | 2.40 % | 0.00 % |
N/A |
N/A |
WELL:SW | HAN-GINS Indxx Healthcare.. | 2.40 % | 0.00 % |
N/A |
N/A |
FFTY | Innovator IBD® 50 ETF | 0.00 % | 0.80 % |
-0.22 (-0.11%) |
USD 0.09B |
FYC | First Trust Small Cap Gro.. | 0.00 % | 0.70 % |
+0.25 (+-0.11%) |
USD 0.27B |
FYX | First Trust Small Cap Cor.. | 0.00 % | 0.63 % |
+0.78 (+-0.11%) |
USD 0.83B |
IBUY | Amplify Online Retail ETF | 0.00 % | 0.65 % |
N/A |
USD 0.18B |
XHS | SPDR® S&P Health Care Se.. | 0.00 % | 0.35 % |
-0.27 (-0.11%) |
USD 0.08B |
WELL:LSE | Hanetf Icav - Han-Gins He.. | 0.00 % | 0.00 % |
N/A |
USD 0.02B |
W311:XETRA | HAN-GINS Indxx Healthcare.. | 0.00 % | 0.00 % |
N/A |
USD 0.02B |
IWFH | iShares Virtual Work and .. | 0.00 % | 0.00 % |
+0.04 (+-0.11%) |
USD 2.99M |
DDOC:XETRA | Global X Telemedicine & D.. | 0.00 % | 0.00 % |
-0.02 (-0.11%) |
USD 5.39M |
W311:F | HAN-GINS Indxx Healthcare.. | 0.00 % | 0.00 % |
-0.04 (-0.11%) |
USD 0.02B |
Market Performance vs. Industry/Classification (Household & Personal Products) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 142.25% | 100% | F | 100% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 142.25% | 88% | B+ | 100% | F | ||
Trailing 12 Months | |||||||
Capital Gain | 154.55% | 100% | F | 99% | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 154.55% | 88% | B+ | 99% | N/A | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 14.38% | 76% | C+ | 79% | B- | ||
Dividend Return | 14.38% | 71% | C- | 75% | C | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 57.56% | 18% | F | 14% | F | ||
Risk Adjusted Return | 24.98% | 47% | F | 47% | F | ||
Market Capitalization | 5.48B | 47% | F | 77% | C+ |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company had positive total cash flow in the most recent four quarters.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The company had negative total free cash flow in the most recent four quarters.